Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes

Sponsor
Novo Nordisk A/S
Study ID
NCT01511692
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    1.8 mg/day injected subcutaneously for 4 weeks
  • placebo — DRUG
    Liraglutide placebo, injected subcutaneously for 4 weeks
  • placebo — DRUG
    Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
  • glimepiride — DRUG
    Dose individually adjusted, administered orally for 4 weeks

Study Details

This trial is conducted in Europe and Oceania. The aim of this trial is to assess the effects of liraglutide on energy intake in subjects with type 2 diabetes.

Key Dates

Start date
Nov 30, 2005
Status verified
Jan 2017
Primary completion
Sep 30, 2007
Completion
Sep 30, 2007

Study Design

Enrollment
43 participants (actual)
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Lira --> placebo
  • Placebo Comparator: Placebo --> glim
  • Active Comparator: Glim --> lira

Primary Outcome Measure

The energy intake at a standardised buffet meal with a preload paradigm quantified using Foodworks 2.10

Related Studies